All companies
Visit website
Lambs
OperatingFaraday Labs Inc
Healthcare · Founded 2018
Apparel that boosts your immune health, cognition, recovery, and sleep
Valuation cap ⓘ
$30.0M
As of Mar 2023 · from Lambs Crowd SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$622,855
Across 2 rounds since 2022
Latest share price
$1.00
Reg CF Offering (2024) offering price
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its source$2.9M
−$993K
2020
$2.9M
−$1.2M
2021
$2.5M
−$1.2M
2022
$2.9M
−$514K
2023
$3.9M
−$317K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$2,869,831
$2,908,972
$2,497,210
$2,900,756
$3,883,184
Cost of goods sold
$1,504,782
$1,417,168
$1,302,660
$1,179,774
$1,459,330
Gross margin
48%
51%
48%
59%
62%
Net income
-$992,659
-$1,224,263
-$1,165,676
-$513,653
-$317,032
Taxes paid
$2,802
$0
$0
$0
$0
Balance sheet
Cash
$193,245
$297,157
$307,803
$700,831
$1,447,323
Accounts receivable
$89
$253
$0
$0
-$134
Total assets
$560,132
$747,166
$734,021
$1,332,728
$2,020,666
Short-term debt
$474,251
$654,462
$162,337
$1,729,379
$112,287
Long-term debt
$0
$0
$694,291
$2,683,768
$0
Total liabilities
$474,251
$654,462
$856,628
$4,413,147
$112,287
Other
Headcount
—
5
4
5
6
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$30.0M
Valuation cap
Lambs Crowd SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $618K
Raised $622.9K / $1.1MInvestors 982Valuation cap $30M
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 3 of 4 annual reports (FY2022–FY2025)
982 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001920988Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.